Aandeel PRN PROFOUND MEDICAL CORP.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Profound Medical Corp.

Aandelen

PRN

CA74319B5027

Beurs gesloten - Toronto S.E.
Andere beurzen
 21:14:51 26-06-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
12,09 CAD +5,13% Intraday-grafiek van Profound Medical Corp. +0,75% +8,92%
15/05 Transcript : Profound Medical Corp. - Shareholder/Analyst Call
14/05 Sectorupdate: Gezondheidszorgaandelen dinsdag stabiel premarket MT

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!
Gratis inschrijven
Profound Medical : MATERIAL CHANGE REPORT Form 6 K
PROFOUND MEDICAL ANNUAL GENERAL MEETING OF SHAREHOLDERS VOTING RESULTS
Sector Update: Health Care Stocks Steady Premarket Tuesday
Profound Medical Receives FDA Approval for AI-Powered Prostate Disease Device --Shares Advance Pre-Bell
Profound Medical Receives U.S. FDA Clearance for "Contouring Assistant" AI Module
Profound Medical Brief: Says Received U.S. FDA 510(k) Clearance for 'Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
Profound Medical Receives U.S. FDA 510(K) Clearance for Contour Assistant AI Module That Enables Creation of an Automated Tulsa Treatment Plan
Profound Reports a Narrower First-Quarter Loss; Provides 2024 Revenue Guidance
Profound Medical Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024
Profound Medical Brief: Expects total revenue for FY24 to be in the range of US$11.0-$12.0 million, which represents 53% to 67% growth compared to its prior year revenue
Profound Medical Brief: Recorded Q1 revenue of approximately $1.91 million, with $1.48 million from recurring revenue; Issues Full-Year 2024 Revenue Guidance
Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance
Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024
Profound Medical Says Clinical Evidence Points to Potential of Its TULSA Procedure as a Treatment for Prostate Cancer
Profound Medical Brief: Adds Clinical evidence Continues to highlight TULSA's "Ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH"
Profound Medical Brief: Says "Growing Body of Clinical Evidence" Points to Potential of Its TULSA Procedure "Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum"
Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers PRN
  4. Nieuws Profound Medical Corp.
  5. Andere talen